ONCAlert | 2018 ASCO Annual Meeting
Videos  >  

An Overview of the BR-002 Trial in Breast Cancer

Julia White, MD
Published Online:7:48 PM, Thu March 27, 2014
Julia White, MD, professor, director, Breast Radiation Oncology, vice chair, Clinical Research, The Ohio State University Comprehensive Cancer Center, discusses the BR-002 trial, which will evaluate the rate of complete tumor ablation of breast cancers that are less than or equal to 2 centimeters.

Clinical Pearls:
  • This trial seeks to confirm that a local intervention does not change the outcome of a patient
  • Participants of the trial will be randomized to ablation or standard treatment
  • Women are only qualified for the trial if they are responding to chemotherapy or are in their first line of chemotherapy​
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.